Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| STXS - Stereotaxis | 21.33% | Hold | 13,680,554 | $6.20 | $85M | — | — |
| Blueprint Medicines | 5.57% | Hold | 206,911 | $107.11 | $22M | — | — |
| FATE - Fate Therapeutics | 5.48% | Add +8.1% | 372,160 | $58.51 | $22M | +27,800 | +$1M |
| Adicet Bio | 3.22% | Add +94.8% | 733,172 | $17.49 | $13M | +356,891 | +$10M |
| XENE - Xenon Pharmaceuticals | 3.16% | Reduce −1.0% | 402,667 | $31.24 | $13M | −3,868 | +$6M |
| Arena Pharmaceuticals | 2.80% | Hold | 119,615 | $92.94 | $11M | — | — |
| IDYA - Ideaya Biosciences | 2.73% | Hold | 460,061 | $23.64 | $11M | — | — |
| DXCM - Dexcom | 2.45% | Reduce −14.2% | 18,138 | $536.94 | $10M | −3,000 | −$2M |
| Karuna Therapeutics | 2.39% | Reduce −2.9% | 72,423 | $130.99 | $9M | −2,162 | +$363K |
| NRIX - Nurix Therapeutics | 2.23% | Hold | 306,320 | $28.95 | $9M | — | — |
| Morphic | 2.16% | Hold | 181,467 | $47.38 | $9M | — | — |
| BHVN - Biohaven | 2.01% | Reduce −34.1% | 58,100 | $137.81 | $8M | −30,000 | −$4M |
| Sage Therapeutics | 1.93% | Hold | 180,306 | $42.54 | $8M | — | — |
| Merus | 1.81% | Add +71.3% | 226,089 | $31.80 | $7M | +94,140 | +$4M |
| NBIX - Neurocrine Biosciences | 1.79% | Reduce −1.2% | 83,655 | $85.17 | $7M | −1,000 | −$994K |
| SNDX - Syndax Pharmaceuticals | 1.63% | Add +267.4% | 296,535 | $21.89 | $6M | +215,833 | +$5M |
| NDAQ - Ishares Tr Nasdaq Biotech | 1.57% | Hold | 40,900 | $152.62 | $6M | — | — |
| CYTK - Cytokinetics | 1.54% | Reduce −23.4% | 134,094 | $45.58 | $6M | −40,906 | −$143K |
| Cymabay Therapeutics | 1.52% | Add +241.0% | 1,787,569 | $3.38 | $6M | +1,263,283 | +$4M |
| Cardiovascular Sys | 1.36% | Add +48.1% | 286,988 | $18.78 | $5M | +93,247 | −$971K |
| RVMD - Revolution Medicines | 1.34% | Add +1.2% | 212,231 | $25.17 | $5M | +2,500 | −$428K |
| ATRC - Atricure | 1.26% | Hold | 72,029 | $69.53 | $5M | — | — |
| RCUS - Arcus Biosciences | 1.19% | Reduce −5.3% | 117,200 | $40.47 | $5M | −6,500 | +$430K |
| Mei Pharma | 1.18% | Add +175.3% | 1,764,846 | $2.67 | $5M | +1,123,846 | +$3M |
| Iveric Bio | 1.16% | Add +27.6% | 275,976 | $16.72 | $5M | +59,625 | +$1M |
| Otonomy | 1.15% | Reduce −7.5% | 2,200,297 | $2.08 | $5M | −179,095 | +$9K |
| Natus Med | 1.14% | Add +99.3% | 190,635 | $23.73 | $5M | +94,982 | +$2M |
| ARAY - Accuray | 1.13% | Hold | 941,800 | $4.77 | $4M | — | — |
| Pardes Biosciences | 0.96% | New | 233,500 | $16.37 | $4M | +233,500 | +$4M |
| F-Star Therapeutics | 0.88% | Hold | 693,785 | $5.02 | $3M | — | — |
| ALEC - Alector | 0.81% | Add +44.5% | 155,247 | $20.65 | $3M | +47,835 | +$755K |
| Affimed | 0.79% | Reduce −40.8% | 571,282 | $5.52 | $3M | −393,575 | −$3M |
| AXGN - Axogen | 0.78% | New | 332,103 | $9.37 | $3M | +332,103 | +$3M |
| Kalvista Pharmaceuticals | 0.63% | Add +0.8% | 190,663 | $13.23 | $3M | +1,500 | −$779K |
| Iteos Therapeutics | 0.63% | Reduce −34.9% | 54,090 | $46.55 | $3M | −28,971 | +$275K |
| LKFT - Galapagos | 0.59% | Reduce −45.1% | 42,675 | $55.14 | $2M | −35,000 | −$2M |
| BMEA - Biomea Fusion | 0.59% | New | 313,923 | $7.45 | $2M | +313,923 | +$2M |
| Rigel Pharmaceuticals | 0.59% | Add +8.7% | 879,000 | $2.65 | $2M | +70,000 | −$608K |
| Holding | 0.56% | Add +10.7% | 46,452 | $47.71 | $2M | +4,500 | −$571K |
| Athira Pharma | 0.53% | Hold | 160,983 | $13.03 | $2M | — | — |
| VKTX - Viking Therapeutics | 0.52% | Hold | 447,400 | $4.60 | $2M | — | — |
| Aerie Pharmaceuticals | 0.51% | Hold | 289,040 | $7.02 | $2M | — | — |
| COGT - Cogent Biosciences | 0.48% | Hold | 223,554 | $8.58 | $2M | — | — |
| 89BIO | 0.48% | Add +14.2% | 144,653 | $13.07 | $2M | +18,001 | −$590K |
| Kinnate Biopharma | 0.47% | Hold | 106,453 | $17.72 | $2M | — | — |
| Mereo Biopharma Group | 0.45% | Hold | 1,126,613 | $1.60 | $2M | — | — |
| Regulus Therapeutics | 0.44% | New | 5,555,555 | $0.3150 | $2M | +5,555,555 | +$2M |
| Venus Concept | 0.42% | Reduce −12.4% | 975,687 | $1.70 | $2M | −137,541 | −$1M |
| IPSC - Century Therapeutics | 0.40% | Add +25.2% | 100,135 | $15.86 | $2M | +20,135 | −$425K |
| KURA - Kura Oncology | 0.39% | Add +9.9% | 110,829 | $14.00 | $2M | +10,000 | −$337K |
| BWAY - Brainsway | 0.39% | Hold | 200,000 | $7.70 | $2M | — | — |
| Surface Oncology | 0.38% | New | 315,000 | $4.78 | $2M | +315,000 | +$2M |
| ASND - Ascendis Pharma A/S | 0.37% | New | 11,000 | $134.55 | $1M | +11,000 | +$1M |
| Macrogenics | 0.36% | Hold | 90,000 | $16.06 | $1M | — | — |
| Ngm Biopharmaceuticals | 0.36% | Add +22.9% | 80,485 | $17.71 | $1M | +15,000 | +$49K |
| Neuronetics | 0.35% | Hold | 313,717 | $4.46 | $1M | — | — |
| Radius Health | 0.33% | Add +1224.0% | 191,978 | $6.92 | $1M | +177,478 | +$1M |
| Theseus Pharmaceuticals | 0.31% | New | 97,500 | $12.68 | $1M | +97,500 | +$1M |
| WVE - Wave Life Sciences | 0.31% | New | 390,161 | $3.14 | $1M | +390,161 | +$1M |
| Nextcure | 0.28% | Add +2.3% | 187,696 | $6.00 | $1M | +4,205 | −$111K |
| BDTX — | 0.28% | New | 206,100 | $5.33 | $1M | +206,100 | +$1M |
| Phasebio Pharmaceuticals | 0.25% | Reduce −37.2% | 378,611 | $2.61 | $988K | −224,431 | −$887K |
| Masimo | 0.22% | Hold | 3,000 | $292.67 | $878K | — | — |
| Mersana Therapeutics | 0.22% | Hold | 140,263 | $6.22 | $872K | — | — |
| Compugen | 0.22% | Hold | 201,502 | $4.30 | $866K | — | — |
| TCOM - Field Trip Health | 0.21% | Hold | 340,900 | $2.46 | $839K | — | — |
| Aslan Pharmaceuticals | 0.21% | Hold | 732,500 | $1.12 | $820K | — | — |
| Harpoon Therapeutics | 0.20% | Hold | 105,163 | $7.55 | $794K | — | — |
| Lava Therapeutics | 0.19% | Hold | 139,332 | $5.50 | $766K | — | — |
| LRMR - Larimar Therapeutics | 0.19% | Add +8.8% | 70,177 | $10.79 | $757K | +5,690 | +$13K |
| Hookipa Pharma | 0.19% | Reduce −0.5% | 320,444 | $2.33 | $747K | −1,680 | −$1M |
| SCYXEUR - Scynexis | 0.19% | New | 121,242 | $6.10 | $740K | +121,242 | +$740K |
| PRQR - Proqr Therapeutics | 0.17% | Reduce −71.2% | 85,476 | $8.01 | $685K | −210,907 | −$2M |
| Sutro Biopharma | 0.17% | Reduce −47.1% | 45,000 | $14.89 | $670K | −40,000 | −$936K |
| CMPX - Compass Therapeutics | 0.16% | New | 196,091 | $3.17 | $622K | +196,091 | +$622K |
| Infinity Pharmaceuticals | 0.13% | Hold | 236,160 | $2.25 | $531K | — | — |
| PHVS - Pharvaris | 0.13% | Add +4.7% | 36,720 | $14.38 | $528K | +1,646 | −$94K |
| Adaptimmune Therapeutics | 0.13% | New | 136,266 | $3.75 | $511K | +136,266 | +$511K |
| INGN - Inogen | 0.13% | Hold | 15,000 | $34.00 | $510K | — | — |
| Bolt Biotherapeutics | 0.12% | Hold | 100,000 | $4.90 | $490K | — | — |
| MDGL - Madrigal Pharmaceuticals | 0.12% | Hold | 5,600 | $84.82 | $475K | — | — |
| Surgalign | 0.10% | Hold | 579,710 | $0.7159 | $415K | — | — |
| ANNX - Annexon | 0.09% | Add +32.2% | 30,796 | $11.49 | $354K | +7,500 | −$80K |
| Genfit S A | 0.08% | Reduce −67.9% | 60,448 | $5.00 | $302K | −128,101 | −$396K |
| Holding | 0.05% | New | 80,000 | $2.45 | $196K | +80,000 | +$196K |
Showing top 50 of 85 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2021 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | 3.14% | Exit | 0 | $20.16 | $12M | −587,456 | −$12M |
| Fs Development Ii · CL A | 0.79% | Exit | 0 | $9.95 | $3M | −299,950 | −$3M |
| Kadmon | 0.73% | Exit | 0 | $8.71 | $3M | −314,561 | −$3M |
| IFRX - Inflarx | 0.41% | Exit | 0 | $2.59 | $2M | −600,000 | −$2M |
| Alpine Immune Sciences | 0.32% | Exit | 0 | $10.67 | $1M | −111,501 | −$1M |
| Vascular Biogenics | 0.03% | Exit | 0 | $2.05 | $113K | −55,000 | −$113K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2